Table 5. Association between neutrophil–lymphocyte ratio/platelet–lymphocyte ratio and mortality in 1101 Asian breast cancer patients by breast cancer subtype.
|
Neutrophil–lymphocyte ratio |
Platelet–lymphocyte ratio |
|||
|---|---|---|---|---|
| ⩽4.00 (n=975) | >4.00 (n=126) | ⩽185 (n=801) | >185 (n=300) | |
|
ER+ or PR+ and HER2− (n=470) | ||||
| Adjusted hazard ratio (95% CI)a | 1.00 | 1.16 (0.61–2.21) | 1.00 | 1.21 (0.80–1.85) |
|
ER+ or PR+ and HER2+ (n=216) | ||||
| Adjusted hazard ratio (95% CI)b | 1.00 | 1.14 (0.65–1.99) | 1.00 | 2.01 (1.23–3.29)c |
|
ER− and PR− and HER2+ (n=207) | ||||
| Adjusted hazard ratio (95% CI)d | 1.00 | 1.63 (1.04–2.55)c | 1.00 | 0.92 (0.60–1.41) |
|
ER− and PR− and HER2− (n=208) | ||||
| Adjusted hazard ratio (95% CI)e | 1.00 | 1.91 (1.00–3.65)c | 1.00 | 1.27 (0.76–2.14)c |
Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER2=Human epidermal growth factor receptor 2; NLR=neutrophil–lymphocyte ratio; PLR=platelet–lymphocyte ratio; PR=progesterone receptor.
Patients with unknown ER, PR or HER2 status, as well as those with equivocal HER2 status without fluorescence in situ hybridisation were excluded. Adjusted hazard ratios were derived using the Cox regression model. Only factors that changed the hazard ratios for NLR >4.0/PLR >185 by more than 10% in the initial bivariable analyses were included in the final multivariable models.
For NLR, the final model was adjusted for race, tumour size, number of positive axillary lymph nodes, distant metastasis, type of surgery, neoadjuvant chemotherapy, and platelet–lymphocyte ratio. For PLR, the final model was adjusted for tumour size, number of positive axillary lymph nodes, distant metastasis, type of surgery, neoadjuvant chemotherapy, and neutrophil–lymphocyte ratio.
For NLR, the final model was adjusted for tumour size, number of positive axillary lymph nodes, distant metastasis, type of surgery, neoadjuvant chemotherapy, and platelet–lymphocyte ratio. For PLR, the final model was adjusted for age at diagnosis, race, tumour size, number of positive axillary lymph nodes, distant metastasis, and neutrophil–lymphocyte ratio.
Statistically significant.
For NLR, the final model was adjusted for tumour size, number of positive axillary lymph nodes, distant metastasis, type of surgery, neoadjuvant chemotherapy, and platelet–lymphocyte ratio. For PLR, the final model was adjusted for tumour size, number of positive axillary lymph nodes, distant metastasis, type of surgery, neoadjuvant chemotherapy, and platelet–lymphocyte ratio.
For NLR, the final model was adjusted for number of positive axillary lymph nodes, type of surgery, neoadjuvant chemotherapy, and platelet–lymphocyte ratio. For PLR, the final model was adjusted for distant metastasis, type of surgery, neoadjuvant chemotherapy, and platelet–lymphocyte ratio.